Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Senft, Daniela ^a   Berking, Carola ^a   Graf, Saskia A ^a   Kammerbauer, Claudia ^a   Ruzicka, Thomas ^a   Besch, Robert ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; FLUOROURACIL; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; BCL2-RELATED PROTEIN A1; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL ACTIVITY; CELL DEATH; CELL SPECIFICITY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; KERATINOCYTE; MELANOMA CELL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RNA INTERFERENCE; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; PRIMARY CELL CULTURE; SKIN; SKIN TUMOR; TUMOR CELL LINE; UPREGULATION;

CELL DEATH; CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SKIN; SKIN NEOPLASMS; SUBSTRATE SPECIFICITY; UP-REGULATION;

EID: 84856196328     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030821     Document Type: Article

References (30)

1. Lawson DH, (2004) Update on the systemic treatment of malignant melanoma. Semin Oncol 31: 33-37.
2. Lens MB, Eisen TG, (2003) Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 4: 2205-2211.
3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
4. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
5. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
6. Green DR, (2000) Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4.
7. Youle RJ, Strasser A, (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
8. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, et al. (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8: 1348-1358.
9. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
10. Evan GI, (2006) Can't kick that oncogene habit. Cancer Cell 10: 345-347.
11. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH, (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science 278: 1064-1068.
12. Cragg MS, Harris C, Strasser A, Scott CL, (2009) Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 9: 321-326.
13. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
14. Bush JA, Li G, (2003) The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis 20: 531-539.
15. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, et al. (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365.
16. Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC, et al. (2010) A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 1: e40.
17. Besch R, Poeck H, Hohenauer T, Senft D, Hacker G, et al. (2009) Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 119: 2399-2411.
18. Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM, et al. (2010) Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 70: 4318-4326.
19. Hassan M, Alaoui A, Feyen O, Mirmohammadsadegh A, Essmann F, et al. (2008) The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. Oncogene 27: 4557-4568.
20. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, et al. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403.
21. Weber A, Kirejczyk Z, Potthoff S, Ploner C, Hacker G, (2009) Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells. Transl Oncol 2: 73-83.
22. Jiang CC, Lucas K, Avery-Kiejda KA, Wade M, deBock CE, et al. (2008) Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res 68: 6708-6717.
23. Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE, (2009) Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 7: 549-556.
24. Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, et al. (2008) Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 6: 42-52.
25. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
26. Plettenberg A, Ballaun C, Pammer J, Mildner M, Strunk D, et al. (1995) Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am J Pathol 146: 651-659.
27. Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Potter R, et al. (1998) Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 8: 197-203.
28. Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, et al. (1998) Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 4: 1865-1871.
29. Van Triest B, Pinedo HM, Giaccone G, Peters GJ, (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11: 385-391.
30. Besch R, Berking C, Kammerbauer C, Degitz K, (2007) Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53. Cell Death Differ 14: 818-829.